Are you Dr. Kapoor?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 34 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
26525 N Riverwoods Blvd
Mettawa, IL 60045Phone+1 847-937-5924- Is this information wrong?
Summary
- Dr. Mudra Kapoor, MD is a family physician in Mettawa, Illinois. She is currently licensed to practice medicine in Illinois.
Education & Training
Adventist Hinsdale HospitalResidency, Family Medicine, 2003 - 2006
Emory University School of MedicineClass of 2003
Certifications & Licensure
IL State Medical License 2005 - 2026
Publications & Presentations
PubMed
- 9 citationsRelationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis.Michael S. Schechter, Suzanne H. Michel, Shufang Liu, B Woun Seo, Mudra Kapoor, Rupal Khurmi, Mark Haupt> ;Journal of Pediatric Gastroenterology and Nutrition. 2018 Oct 1
- 53 citationsEfficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.Gregory J. Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Y. Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne ...> ;Journal of Hepatology. 2016 Jan 1
- 34 citationsExploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionEric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, Michael J. Bennett, Fred Poordad, Mudra Kapoor, Prajakta S. Badri, Campbell Andrew L, Lino Rodrigues, Yiran Hu, T...> ;The Journal of Infection. 2015 Feb 1
Press Mentions
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation CongressDecember 6th, 2022- AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International CongressSeptember 15th, 2022
- New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (Upadacitinib) in Patients with Rheumatoid Arthritis to Be Presented at EULAR 2021 Virtual CongressJune 2nd, 2021
- Join now to see all
